Fragmented Lactic Acid Bacterial Cells Activate Peroxisome Proliferator-Activated Receptors and Ameliorate Dyslipidemia in Obese Mice

Recent studies suggest that peroxisome proliferator-activated receptor (PPAR) activation ameliorates metabolic disorders, including dyslipidemia. To identify an effective PPAR agonist, we screened the in vitro PPARα/γ activation ability of organic solvent extracts from food-oriented bacterial strain...

Full description

Saved in:
Bibliographic Details
Published inJournal of agricultural and food chemistry Vol. 64; no. 12; pp. 2549 - 2559
Main Authors Nakamura, Futoshi, Ishida, Yu, Sawada, Daisuke, Ashida, Nobuhisa, Sugawara, Tomonori, Sakai, Manami, Goto, Tsuyoshi, Kawada, Teruo, Fujiwara, Shigeru
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 30.03.2016
Subjects
Animals
Atherosclerosis - blood
Dyslipidemias - blood
Insulin Resistance - physiology
Lactic Acid - pharmacology
Lipoproteins, HDL - blood
Lipoproteins, LDL - blood
Mice
Mice, Obese
Obesity - blood
PPAR alpha - agonists
PPAR gamma - agonists
Triglycerides - metabolism
cell fragmentation
dyslipidemia
peroxisome proliferator-activated receptors
lactic acid bacteria
Online AccessGet full text

Cover

More Information
Summary:Recent studies suggest that peroxisome proliferator-activated receptor (PPAR) activation ameliorates metabolic disorders, including dyslipidemia. To identify an effective PPAR agonist, we screened the in vitro PPARα/γ activation ability of organic solvent extracts from food-oriented bacterial strains belonging to 5 genera and 32 species, including lactic acid bacteria, and of these, Lactobacillus amylovorus CP1563 demonstrated the highest PPARα/γ agonist activity. We also found that physical fragmentation of the strain could substitute organic solvent extraction for the expression of CP1563 activity in vitro. For functional food manufacturing, we selected the fragmented CP1563 and conducted subsequent animal experiments. In an obese mouse model, we found that treatment with fragmented CP1563 for 12 weeks decreased the levels of low-density lipoprotein (LDL)-cholesterol and triglyceride in plasma, significantly decreased the atherosclerosis index, and increased the plasma high-density lipoprotein (HDL)-cholesterol level. Thus, we conclude that fragmented CP1563 may be a candidate for the prevention and treatment of dyslipidemia.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0021-8561
1520-5118
DOI:10.1021/acs.jafc.5b05827